Changing Lives through Medical Innovation
AGA Medical Corporation is dedicated to the development of innovative products that address significant unmet medical needs and become the standard of care.
The AMPLATZER® Septal Occluder is the first catheter delivered atrial septal closure device approved in the United States. Atrial septal defects are caused by incomplete growth of the tissue wall (septum) that separates the upper chambers of the heart (atria).
The AMPLATZER® Duct Occluder is designed to allow closure of the patent ductus arteriosus using a minimally-invasive catheter procedure instead of surgery. Patent ductus arteriosus is a communication (blood vessel) between the pulmonary artery and aorta.
The AMPLATZER® Muscular VSD Occluder is designed for complex ventricular septal defect repair in patients considered to be high risk for standard transatrial or transarterial surgical repair. Ventricular septal defects are caused by incomplete growth of the tissue wall (septum) that separates the lower chambers of the heart (ventricles).
|
|
The devices in the AMPLATZER® Vascular Plug Family block (embolize) peripheral veins and arteries to reduce or eliminate blood flow to a targeted organ, or to reroute blood flow through other vessels.
AGA Medical Corporation products are delivered using specially designed accessories for access, assessment, preparation and delivery.
|
Current Clinical Trials
 |
Respect Trial - United States
AMPLATZER® PFO Occluder - Notice of Availability - Caution: Investigational device. Limited by Federal (U.S.) law to investigational use. |
|
|
 |
Premium Trial - United States
AMPLATZER® PFO Occluder - Notice of Availability - Caution: Investigational device. Limited by Federal (U.S.) law to investigational use. |